Erin G Nicholson1, Chelsea Schlegel2, Roberto P Garofalo3, Reena Mehta4, Margaret Scheffler5, Minghua Mei6, Pedro A Piedra7. 1. Department of Pediatric. 2. Department of Allergy & ENT Associates, The Woodlands. 3. Department of Pediatrics, University of Texas Medical Branch, Galveston. 4. Allergy & Asthma Specialists, Saddle River, New Jersey. 5. Department of Pediatrics, Warren Alpert Medical School of Brown University, Providence, Rhode Island. 6. Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston. 7. Department of Pediatric Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston.
Abstract
BACKGROUND: Bronchiolitis causes substantial disease in young children. Previous findings had indicated that a robust innate immune response was not associated with a poor clinical outcome in bronchiolitis. This study tested the hypothesis that increased concentrations of cytokines and chemokines in nasal wash specimens were associated with decreased severity in bronchiolitis. METHODS: Children <24 months old who presented to the emergency department with signs and symptoms of bronchiolitis were eligible for enrollment. Nasal wash specimens were analyzed for viral pathogens and cytokine/chemokine concentrations. These results were evaluated with regard to disposition. RESULTS: One hundred eleven children with bronchiolitis were enrolled. A viral pathogen was identified in 91.9% of patients (respiratory syncytial virus in 51.4%, human rhinovirus in 11.7%). Higher levels of cytokines and chemokines (interferon [IFN] γ; interleukin [IL] 4, 15, and 17; CXCL10; and eotaxin) were significantly associated with a decreased risk of hospitalization. IL-17, IL-4, IFN-γ, and IFN-γ-inducible protein 10 (CXCL10 or IP-10) remained statistically significant in the multivariate analyses. CONCLUSIONS: The cytokines and chemokines significantly associated with decreased bronchiolitis severity are classified in a wide range of functional groups (T-helper 1 and 2, regulatory, and chemoattractant). The involvement of these functional groups suggest that a broadly overlapping cytokine/chemokine response is required for control of virus-mediated respiratory disease in young children.
BACKGROUND:Bronchiolitis causes substantial disease in young children. Previous findings had indicated that a robust innate immune response was not associated with a poor clinical outcome in bronchiolitis. This study tested the hypothesis that increased concentrations of cytokines and chemokines in nasal wash specimens were associated with decreased severity in bronchiolitis. METHODS:Children <24 months old who presented to the emergency department with signs and symptoms of bronchiolitis were eligible for enrollment. Nasal wash specimens were analyzed for viral pathogens and cytokine/chemokine concentrations. These results were evaluated with regard to disposition. RESULTS: One hundred eleven children with bronchiolitis were enrolled. A viral pathogen was identified in 91.9% of patients (respiratory syncytial virus in 51.4%, human rhinovirus in 11.7%). Higher levels of cytokines and chemokines (interferon [IFN] γ; interleukin [IL] 4, 15, and 17; CXCL10; and eotaxin) were significantly associated with a decreased risk of hospitalization. IL-17, IL-4, IFN-γ, and IFN-γ-inducible protein 10 (CXCL10 or IP-10) remained statistically significant in the multivariate analyses. CONCLUSIONS: The cytokines and chemokines significantly associated with decreased bronchiolitis severity are classified in a wide range of functional groups (T-helper 1 and 2, regulatory, and chemoattractant). The involvement of these functional groups suggest that a broadly overlapping cytokine/chemokine response is required for control of virus-mediated respiratory disease in young children.
Authors: Guillermina A Melendi; Federico R Laham; A Clara Monsalvo; Javier M Casellas; Victor Israele; Norberto R Polack; Steven R Kleeberger; Fernando P Polack Journal: Pediatrics Date: 2007-08 Impact factor: 7.124
Authors: Shawn L Ralston; Allan S Lieberthal; H Cody Meissner; Brian K Alverson; Jill E Baley; Anne M Gadomski; David W Johnson; Michael J Light; Nizar F Maraqa; Eneida A Mendonca; Kieran J Phelan; Joseph J Zorc; Danette Stanko-Lopp; Mark A Brown; Ian Nathanson; Elizabeth Rosenblum; Stephen Sayles; Sinsi Hernandez-Cancio Journal: Pediatrics Date: 2014-11 Impact factor: 7.124
Authors: Berkeley L Bennett; Roberto P Garofalo; Stanley G Cron; Yashoda M Hosakote; Robert L Atmar; Charles G Macias; Pedro A Piedra Journal: J Infect Dis Date: 2007-04-12 Impact factor: 5.226
Authors: Christophe Marguet; Nathalie Bocquel; Jacques Benichou; Jean Pierre Basuyau; Marie France Hellot; Laure Couderc; Eric Mallet; Bertrand Macé Journal: Pediatr Allergy Immunol Date: 2007-12-18 Impact factor: 6.377
Authors: Tim Flerlage; Aisha Souquette; E Kaitlynn Allen; Timothy Brahm; Jeremy Chase Crawford; Li Tang; Yilun Sun; Gabriela Maron; Joshua Wolf; Brandon Triplett; Paul G Thomas Journal: Am J Respir Cell Mol Biol Date: 2020-09 Impact factor: 6.914
Authors: Ryan S Thwaites; Matthew Coates; Kazuhiro Ito; Marwa Ghazaly; Calandra Feather; Farhana Abdulla; Tanushree Tunstall; Pooja Jain; Lindsey Cass; Garth Rapeport; Trevor T Hansel; Simon Nadel; Peter Openshaw Journal: Am J Respir Crit Care Med Date: 2018-10-15 Impact factor: 21.405
Authors: Carlos E Rodríguez-Martínez; Jose A Castro-Rodriguez; Gustavo Nino; Fabio Midulla Journal: Paediatr Respir Rev Date: 2019-04-12 Impact factor: 2.726
Authors: Maximillian S Habibi; Ryan S Thwaites; Christopher Chiu; Peter J M Openshaw; Meiping Chang; Agnieszka Jozwik; Allan Paras; Freja Kirsebom; Augusto Varese; Amber Owen; Leah Cuthbertson; Phillip James; Tanushree Tunstall; David Nickle; Trevor T Hansel; Miriam F Moffatt; Cecilia Johansson Journal: Science Date: 2020-10-09 Impact factor: 63.714